NASDAQ · TECH
Healthcare · Biotechnology
$72.40
Up+$0.00 (+0.00%)
Updated Oct 3, 2026, 3:40 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · TECH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
TECH closed at $72.40 after 20 trading sessions, down 0.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $72.44 | $72.47 | $72.38 | $72.40 | 1.87M |
| Oct 1, 2026 | $72.50 | $72.54 | $72.38 | $72.40 | 2.71M |
| Sep 30, 2026 | $72.38 | $72.55 | $72.33 | $72.47 | 3.14M |
| Sep 29, 2026 | $72.36 | $72.50 | $72.36 | $72.38 | 3.36M |
| Sep 28, 2026 | $72.58 | $72.65 | $72.485 | $72.51 | 3.82M |
| Sep 25, 2026 | $72.59 | $72.64 | $72.555 | $72.61 | 2.18M |
| Sep 24, 2026 | $72.54 | $72.63 | $72.51 | $72.57 | 2.99M |
| Sep 23, 2026 | $72.50 | $72.64 | $72.48 | $72.52 | 3.56M |
| Sep 22, 2026 | $72.52 | $72.69 | $72.46 | $72.55 | 3.44M |
| Sep 21, 2026 | $72.50 | $72.54 | $72.44 | $72.47 | 4.67M |
| Sep 18, 2026 | $72.41 | $72.44 | $72.26 | $72.37 | 5.02M |
| Sep 17, 2026 | $72.36 | $72.48 | $72.28 | $72.41 | 3.78M |
| Sep 16, 2026 | $72.35 | $72.365 | $72.22 | $72.33 | 3.65M |
| Sep 15, 2026 | $72.28 | $72.39 | $72.205 | $72.34 | 2.93M |
| Sep 14, 2026 | $72.21 | $72.299 | $72.17 | $72.27 | 2.74M |
| Sep 11, 2026 | $72.15 | $72.38 | $72.12 | $72.12 | 2.72M |
| Sep 10, 2026 | $72.28 | $72.325 | $72.08 | $72.08 | 3.82M |
| Sep 9, 2026 | $72.30 | $72.365 | $72.23 | $72.25 | 1.99M |
| Sep 8, 2026 | $72.37 | $72.46 | $72.29 | $72.31 | 2.07M |
| Sep 4, 2026 | $72.40 | $72.48 | $72.40 | $72.43 | 1.86M |
The latest Smart Investors Daily articles mentioning TECH.
Company
Market Activity
Research & News
TECH research
Company profile and research snapshot.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 9, 2026 | RBC Capital | Sector Perform | — |
| Jun 30, 2026 | TD Cowen | Hold | — |
| Jun 30, 2026 | Benchmark | Hold | — |
| Jun 29, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 26, 2026
Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]
Benzinga · Sep 25, 2026
Robert V Baumgartner, Board Member at Bio-Techne (NASDAQ:TECH), reported a large exercise of company stock options on September 24, according to a new SEC filing. What Happened: In an insider options exercise disclosed
Yahoo · Sep 24, 2026
Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.
Yahoo · Sep 23, 2026
Bio-Techne has had an impressive run over the past six months as its shares have beaten the S&P 500 by 21.5%. The stock now trades at $72.56, marking a 39.5% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TECH.
